|Articles|January 3, 2012

Psychotropic medications and renal failure

Antidepressants - SSRIs

Escitalopram (Lexapro)

Citalopram (Celexa)

Fluoxetine (Prozac, Sarafem)

Fluvoxamine (Luvox)

Paroxetine (Paxil)

Sertraline (Zoloft)

Antidepressants - Tricyclics

Amitriptyline (Elavil)

Clomipramine (Anafranil)

Desipramine (Norpramin)

Doxepin (Sinequan)

Imipramine (Tofranil)

Nortryptiline (Aventyl, Pamelor)

Antidepressants - Other

Bupropion (Wellbutrin, Zyban)

Duloxetine (Cymbalta)

Maprotiline (Ludiomil)

Mirtazapine (Remeron)

Venlafaxine (Effexor)

Antimanic agents

Lithium (Eskalith, Lithobid, Lithonate)

Antipsychotics - Atypical^a

Aripiprazole (Abilify)

Clozapine (Clozaril)

Olanzapine (Zyprexa)

Quetiapine (Seroquel)

Risperidone (Risperdal)

Ziprasidone (Geodon)

Antipsychotics - Typical

Chlorpromazine (Thorazine)

Haloperidol (Haldol)

Anxiolytics and Hypnotics

Eszopiclone (Lunesta)

Ramelteon (Rozerem)

Zaleplon (Sonata)

Zolpidem (Ambien)

Anticonvulsants

Carbamazepine (Tegretol)

Gabapentin (Neurontin)

Lamotrigine (Lamictil)

Oxcarbazepine (Trileptal)

Phenobarbital (Luminal)

Phenytoin (Dilantin)

Pregabalin (Lyrica)

Topirimate (Topomax)

Valproic acid (valproate or divalproex) (Depakene, Depakote)

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

AD04 Application Submitted to FDA Commissioner’s National Priority Voucher Pilot Program for Potential Expedited Review

ByLeah Kuntz

April 27th 2026

AD04 for Alcohol Use Disorder: Favorable Feedback From FDA Following End of Phase 2 Meeting

ByLeah Kuntz

September 16th 2025

FDA Grants Fast Track Designation to Pemvidutide for Treatment of Alcohol Use Disorder

ByLeah Kuntz

August 19th 2025

End of Phase 2 Meeting With the FDA: Adial Prepares to Advance AD04 for Alcohol Use Disorder

ByLeah Kuntz

August 6th 2025

Differences in Experiences Must Influence Interventions

BySara Luciano

July 14th 2025

Latest CME

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Psychotropic medications and renal failure

Antidepressants - SSRIs

Antidepressants - Tricyclics

Antidepressants - Other

Antimanic agents

Antipsychotics - Atypical^a

Antipsychotics - Typical

Anxiolytics and Hypnotics

Anticonvulsants

Related Content

AD04 Application Submitted to FDA Commissioner’s National Priority Voucher Pilot Program for Potential Expedited Review

AD04 for Alcohol Use Disorder: Favorable Feedback From FDA Following End of Phase 2 Meeting

FDA Grants Fast Track Designation to Pemvidutide for Treatment of Alcohol Use Disorder

End of Phase 2 Meeting With the FDA: Adial Prepares to Advance AD04 for Alcohol Use Disorder

Differences in Experiences Must Influence Interventions

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

Vol 43, Issue 9 - Interactive

Debunking the Top 10 Misleading Claims About Antidepressants

Positive Topline Results From Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

Morning Rounds: September 7-14

Psychotropic medications and renal failure

Antidepressants - SSRIs

Antidepressants - Tricyclics

Antidepressants - Other

Antimanic agents

Antipsychotics - Atypicala

Antipsychotics - Typical

Anxiolytics and Hypnotics

Anticonvulsants

Related Content

AD04 Application Submitted to FDA Commissioner’s National Priority Voucher Pilot Program for Potential Expedited Review

AD04 for Alcohol Use Disorder: Favorable Feedback From FDA Following End of Phase 2 Meeting

FDA Grants Fast Track Designation to Pemvidutide for Treatment of Alcohol Use Disorder

End of Phase 2 Meeting With the FDA: Adial Prepares to Advance AD04 for Alcohol Use Disorder

Differences in Experiences Must Influence Interventions

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

Vol 43, Issue 9 - Interactive

Debunking the Top 10 Misleading Claims About Antidepressants

Positive Topline Results From Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

Morning Rounds: September 7-14

Antipsychotics - Atypical^a